Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 6.75
(0.0%)
CNY 6.75
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 66.15 Million CNY | -21.69% |
| 2022 | 77.44 Million CNY | 29.78% |
| 2021 | 34.17 Million CNY | 7.76% |
| 2020 | 54.93 Million CNY | 59.4% |
| 2019 | -82.52 Million CNY | -52.67% |
| 2018 | 71.1 Million CNY | 13.8% |
| 2017 | -177.24 Million CNY | -32.03% |
| 2016 | 93.82 Million CNY | -3.56% |
| 2015 | 101.4 Million CNY | -12.26% |
| 2014 | 113.3 Million CNY | -42.14% |
| 2013 | 195.67 Million CNY | 741.21% |
| 2012 | 6 Million CNY | -36.61% |
| 2011 | 36.96 Million CNY | -3.63% |
| 2010 | 39.01 Million CNY | 64.17% |
| 2009 | 24.24 Million CNY | 3.79% |
| 2008 | 22.89 Million CNY | -36.19% |
| 2007 | 35.63 Million CNY | 21.41% |
| 2006 | 29.23 Million CNY | 46.01% |
| 2005 | 20.06 Million CNY | 290.53% |
| 2004 | 5.36 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -767.88 Thousand CNY | -144.95% |
| 2024 Q1 | 4.64 Million CNY | -29.77% |
| 2024 Q2 | 1.7 Million CNY | -86.03% |
| 2023 Q4 | 12.63 Million CNY | 131.42% |
| 2023 Q1 | 13.44 Million CNY | -49.47% |
| 2023 FY | - CNY | -21.69% |
| 2023 Q2 | 7.41 Million CNY | -44.83% |
| 2023 Q3 | 5.46 Million CNY | -26.38% |
| 2022 Q1 | 3.95 Million CNY | -79.46% |
| 2022 Q4 | 26.61 Million CNY | 70.02% |
| 2022 Q3 | 15.65 Million CNY | 86.37% |
| 2022 FY | - CNY | 29.78% |
| 2022 Q2 | 8.39 Million CNY | 112.1% |
| 2021 Q1 | 6.6 Million CNY | -72.67% |
| 2021 Q3 | 8.4 Million CNY | 1403.33% |
| 2021 Q4 | 19.27 Million CNY | 129.39% |
| 2021 FY | - CNY | 7.76% |
| 2021 Q2 | -644.84 Thousand CNY | -109.76% |
| 2020 FY | - CNY | 59.4% |
| 2020 Q2 | -3.5 Million CNY | -172.0% |
| 2020 Q1 | 4.86 Million CNY | 124.56% |
| 2020 Q4 | 24.16 Million CNY | 403.69% |
| 2020 Q3 | 4.79 Million CNY | 237.06% |
| 2019 Q3 | 9.77 Million CNY | 19.4% |
| 2019 Q2 | 8.18 Million CNY | -24.47% |
| 2019 Q1 | 10.83 Million CNY | -59.91% |
| 2019 Q4 | -19.79 Million CNY | -302.58% |
| 2019 FY | - CNY | -52.67% |
| 2018 Q3 | 7.92 Million CNY | 27.11% |
| 2018 Q1 | 9.27 Million CNY | -61.57% |
| 2018 Q2 | 6.23 Million CNY | -32.77% |
| 2018 FY | - CNY | 13.8% |
| 2018 Q4 | 27.02 Million CNY | 240.97% |
| 2017 Q1 | 11.33 Million CNY | -75.93% |
| 2017 FY | - CNY | -32.03% |
| 2017 Q4 | 24.13 Million CNY | 1225.59% |
| 2017 Q3 | 1.82 Million CNY | -14.13% |
| 2017 Q2 | 2.12 Million CNY | -81.29% |
| 2016 FY | - CNY | -3.56% |
| 2016 Q1 | 9.96 Million CNY | -71.35% |
| 2016 Q2 | 9.96 Million CNY | -0.01% |
| 2016 Q4 | 47.07 Million CNY | 398.06% |
| 2016 Q3 | 9.45 Million CNY | -5.19% |
| 2015 FY | - CNY | -12.26% |
| 2015 Q4 | 34.8 Million CNY | 186.3% |
| 2015 Q3 | 12.15 Million CNY | -53.8% |
| 2015 Q2 | 26.31 Million CNY | 92.15% |
| 2015 Q1 | 13.69 Million CNY | -66.8% |
| 2014 Q3 | 11.48 Million CNY | -39.74% |
| 2014 Q4 | 41.23 Million CNY | 259.05% |
| 2014 Q1 | 20.8 Million CNY | -88.04% |
| 2014 FY | - CNY | -42.14% |
| 2014 Q2 | 19.05 Million CNY | -8.41% |
| 2013 Q3 | 3.87 Million CNY | -47.02% |
| 2013 Q4 | 174.03 Million CNY | 4386.66% |
| 2013 FY | - CNY | 741.21% |
| 2013 Q1 | 1.23 Million CNY | -91.2% |
| 2013 Q2 | 7.32 Million CNY | 491.81% |
| 2012 Q4 | 14.05 Million CNY | 1383.94% |
| 2012 Q1 | -4.29 Million CNY | -118.35% |
| 2012 Q3 | 946.84 Thousand CNY | 143.02% |
| 2012 FY | - CNY | -36.61% |
| 2012 Q2 | -2.2 Million CNY | 48.81% |
| 2011 Q2 | 4.05 Million CNY | -20.05% |
| 2011 Q4 | 23.43 Million CNY | 1430.74% |
| 2011 Q3 | -1.76 Million CNY | -143.43% |
| 2011 Q1 | 5.07 Million CNY | -79.15% |
| 2011 FY | - CNY | -3.63% |
| 2010 Q2 | 6.77 Million CNY | 333.18% |
| 2010 FY | - CNY | 64.17% |
| 2010 Q3 | 71.5 Thousand CNY | -98.95% |
| 2010 Q1 | 1.56 Million CNY | -86.17% |
| 2010 Q4 | 24.31 Million CNY | 33908.09% |
| 2009 Q2 | 3.48 Million CNY | 13.76% |
| 2009 Q3 | 2.4 Million CNY | -30.88% |
| 2009 Q4 | 11.31 Million CNY | 370.47% |
| 2009 FY | - CNY | 3.79% |
| 2009 Q1 | 3.05 Million CNY | -52.01% |
| 2008 Q4 | 6.37 Million CNY | 52.84% |
| 2008 Q2 | 4.84 Million CNY | 20.56% |
| 2008 Q1 | 4.02 Million CNY | -73.88% |
| 2008 FY | - CNY | -36.19% |
| 2008 Q3 | 4.17 Million CNY | -13.97% |
| 2007 FY | - CNY | 21.41% |
| 2007 Q2 | 8.18 Million CNY | 93.72% |
| 2007 Q1 | 4.22 Million CNY | -65.94% |
| 2007 Q3 | 5.64 Million CNY | -31.1% |
| 2007 Q4 | 15.39 Million CNY | 172.91% |
| 2006 Q3 | 5.4 Million CNY | 0.0% |
| 2006 Q4 | 12.41 Million CNY | 129.73% |
| 2006 FY | - CNY | 46.01% |
| 2005 FY | - CNY | 290.53% |
| 2004 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 1.14 Billion CNY | 94.206% |
| Zhejiang Zhenyuan Share Co., Ltd. | 220.46 Million CNY | 69.995% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -83.34 Million CNY | 179.372% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -2.67 Million CNY | 2575.951% |
| Yifan Pharmaceutical Co., Ltd. | -483.52 Million CNY | 113.681% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 4.85 Billion CNY | 98.638% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 116.49 Million CNY | 43.215% |
| Boai NKY Medical Holdings Ltd. | 665.28 Million CNY | 90.057% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 391.09 Million CNY | 83.086% |